Brokers Set Expectations for SRPT FY2024 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities researchers at HC Wainwright issued their FY2024 earnings per share estimates for Sarepta Therapeutics in a note issued to investors on Monday, November 25th. HC Wainwright analyst M. Kapoor expects that the biotechnology company will earn $2.30 per share for the year. HC Wainwright has a “Sell” rating and a $80.00 price objective on the stock. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.07 per share. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.53 EPS, Q1 2025 earnings at $2.32 EPS, Q2 2025 earnings at $2.69 EPS, Q3 2025 earnings at $2.75 EPS, Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $10.58 EPS.

Several other equities analysts also recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They issued a “buy” rating and a $165.00 price objective on the stock. Robert W. Baird dropped their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Citigroup decreased their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Finally, Evercore ISI lowered their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Stock Up 5.7 %

SRPT stock opened at $137.94 on Wednesday. Sarepta Therapeutics has a 1-year low of $78.67 and a 1-year high of $173.25. The business’s 50 day simple moving average is $121.90 and its 200 day simple moving average is $131.39. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $13.18 billion, a PE ratio of 104.40 and a beta of 0.81.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Farallon Capital Management LLC raised its position in shares of Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after acquiring an additional 1,243,427 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of Sarepta Therapeutics in the third quarter valued at approximately $79,425,000. Janus Henderson Group PLC grew its holdings in Sarepta Therapeutics by 14.2% during the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after buying an additional 543,143 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in Sarepta Therapeutics by 693.7% in the 2nd quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after buying an additional 317,277 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 14.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.